Mid-Gestation Preeclampsia Screening Test Successfully Validated
By LabMedica International staff writers Posted on 18 Jul 2012 |
A mid-gestation preeclampsia-screening test correctly identifies 80% of women at risk for the development of preterm preeclampsia.
Pronota’s (Ghent, Belgium) assay, which tests for five protein biomarkers such that in conjunction with blood pressure measurement offers an improvement to existing tests. Proteomics platforms of Pronota were used to identify, verify, and validate a panel of novel blood biomarkers, which are predictive of preeclampsia at the mid-gestation time point. An unbiased large-scale proteomics biomarker-discovery experiment was followed by verification of the results in 300 women who either subsequently developed preeclampsia or did not.
The predictive merit of the biomarker panel was subsequently confirmed in another study of 300 women from a different population. In this validation study, the screening test identified 80% of the women who developed preeclampsia that resulted in birth of a premature baby (preterm preeclampsia). Pronota achieved these results through a longstanding scientific collaboration with Prof. Baker from the University of Alberta (Edmonton, AB, Canada), Prof. North from King’s College, London (United Kingdom), and Dr. Myers from Manchester Maternal & Fetal Health Research Center (United Kingdom).
The cohort used for the study was compiled by the the SCreening fOr Pregnancy Endpoints (SCOPE) Consortium who collected blood samples and gathered medical and lifestyle information from 5,600 women in six centers across Australia, New Zealand, the UK, and the Republic of Ireland over eight years. This controlled prospective study using high quality plasma samples and clinical data allowed for the rigorous and stepwise validation of Pronota’s test.
Dr. Jenny Myers, clinical senior lecturer, Manchester Maternal & Fetal Health Research Centre (United Kingdom) will present a discussion of the Pronota-SCOPE study at the International Society for the Study of Hypertension in Pregnancy meeting in Geneva (Switzerland) in July 2012.
Related Links:
Pronota
University of Alberta
King’s College, London
Pronota’s (Ghent, Belgium) assay, which tests for five protein biomarkers such that in conjunction with blood pressure measurement offers an improvement to existing tests. Proteomics platforms of Pronota were used to identify, verify, and validate a panel of novel blood biomarkers, which are predictive of preeclampsia at the mid-gestation time point. An unbiased large-scale proteomics biomarker-discovery experiment was followed by verification of the results in 300 women who either subsequently developed preeclampsia or did not.
The predictive merit of the biomarker panel was subsequently confirmed in another study of 300 women from a different population. In this validation study, the screening test identified 80% of the women who developed preeclampsia that resulted in birth of a premature baby (preterm preeclampsia). Pronota achieved these results through a longstanding scientific collaboration with Prof. Baker from the University of Alberta (Edmonton, AB, Canada), Prof. North from King’s College, London (United Kingdom), and Dr. Myers from Manchester Maternal & Fetal Health Research Center (United Kingdom).
The cohort used for the study was compiled by the the SCreening fOr Pregnancy Endpoints (SCOPE) Consortium who collected blood samples and gathered medical and lifestyle information from 5,600 women in six centers across Australia, New Zealand, the UK, and the Republic of Ireland over eight years. This controlled prospective study using high quality plasma samples and clinical data allowed for the rigorous and stepwise validation of Pronota’s test.
Dr. Jenny Myers, clinical senior lecturer, Manchester Maternal & Fetal Health Research Centre (United Kingdom) will present a discussion of the Pronota-SCOPE study at the International Society for the Study of Hypertension in Pregnancy meeting in Geneva (Switzerland) in July 2012.
Related Links:
Pronota
University of Alberta
King’s College, London
Latest Molecular Diagnostics News
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset